Two-Year Data For ORENCIA(R) (abatacept) Demonstrate Continued Efficacy In Adults With Rheumatoid Arthritis

Fri, 10 Nov 2006 02:00 PM EST

... Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of ORENCIA(R) (abatacept) in adult patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate and TNF antagonists. [click link for full article] ...